All News

EULAR,poster

EULAR 2021 – Day 1 Report

d Jack Cush, MD

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Read Article
EULAR,Podcast,2021

EULAR 2021 - Day 1 Podcasts

d Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 1 broadcasts below.



You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com



Listen by Clicking below:



Day 1a

Read Article
You put a pt on a #Jaki What is most likely infection that will occur? #EULAR2021 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

So how do irAEs work? Dr. Anne Bass @lovetolearn27 @HSpecialSurgery gives #EULAR2021 a possible conceptual framework @LCalabreseDO @CCalabreseDO @cappelliMD @got_rheum @MarieKostine and so many other good people! @RheumNow https://t.co/5eOZDwkGO6
David Liew drdavidliew ( View Tweet)
An original way of differentiating RA from PsA! The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of -HC 94% -RA 84% -PsA 89% and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310
Aurelie Najm AurelieRheumo ( View Tweet)
Presentation 3480 at #EULAR2021. Your patient is on CellCept, has negative COVID spike IgG and IgM antibodies after vaccination with mRNA vaccination x2. What do you counsel on this test? @RheumNow

Eric Dein ejdein1 ( View Tweet)

Anifrolumab pooled TULIP-1&-2 data on rash and arthritis in SLE more effective in pts with high IFN signals (pts with low IFN may benefit, but they had less rash but more arthritis)- Dr. J Merrill #OP0131 #EULAR2021 @rheumnow

k dao KDAO2011 ( View Tweet)

@KDAO2011 @RheumNow @LupusDocLim @Lupusdoc1 @LupusMD Check this! (top left corner) #HCQ #Lupus #EULAR2021 Link: https://t.co/RQcWoStJtP https://t.co/96l1FvYDQH

Links:

Laurent ARNAUD Lupusreference ( View Tweet)
⬆️prevalence of HCQ retinopathy: Kaiser Permanente 676 pts retrospect study #OP0133 👉6.8% (n=46) had HCQ retinopathy w/ risks: 👉age>80 (OR 3.83) 👉h/o atherosclerosis (OR 2.99), 👉cum. dose >2000 mg (OR 15.8) 👉10-15 yrs use (OR 4.44) 👉>15 yrs (OR 19) #EULAR2021 @rheumnow https://t.co/QA8HHXdnjL
k dao KDAO2011 ( View Tweet)
News: Featured Abstracts from Industry at EULAR 2021 https://t.co/hIBYUdHTLf https://t.co/LTTJ3WPl7X

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR Presentation 3478: Infection risk with surgeries: ⭐️Continue conventional DMARD ⭐️Some risk with biologics, may be confounder and no association with timing of infusions ⭐️Steroids are major risk factor! Esp >10 mg/d ⭐️Recommendations shown ⭐️Address other risks! @rheumnow https://t.co/Bi02d4p9Mw
Eric Dein ejdein1 ( View Tweet)
COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #EULAR2021 poster #POS0912 @RheumNow https://t.co/W2YoyA4K14 https://t.co/lv0GLU2WTF

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021: Great talk by Dr. McFarland recapping the evidence for managing fibromyalgia. ➡️Over a 6 month time period, costs were significantly lower for people receiving psychological therapies compared to those receiving usual care as shown by Cabral et al. @RheumNow https://t.co/RAkUSeNESy
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow

Eric Dein ejdein1 ( View Tweet)

What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Prednisone are Impt. Piling up risk factors is often multiplied! Biggest risk of serious infection and is recurrent serious infection! #EULAR2021 Meet the expert AbbVie session @RheumNow https://t.co/6m0OfsNF1W
Janet Pope Janetbirdope ( View Tweet)
Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & research from 5 centers in Berlin, 104 PsA pts. Let's get more studies to better understand the power of this measure. Poster #POS1069 #EULAR2021 @RheumNow https://t.co/X4UWGwH5i5 https://t.co/J7EpOjTjhe

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Dr Lukas presents data showing possibility of tapering a range of TNF in AxSpA patients in remission 162/184 (88.0%) LDA in progressive spacing group vs 173/189 (91.5%) in continued at 1 year.@RheumNow #EULAR2021 Abstr#0138

Richard Conway RichardPAConway ( View Tweet)

Honoured to be part of the irAE session at #EULAR2021, with some great talks (and then also mine), including: - Anne Bass @lovetolearn27 @HSpecialSurgery on irAE mechanisms - Maria Suarez-Almazor @MDAndersonNews on irAEs in the clinic Well worth tuning into! @RheumNow https://t.co/MN1IcLKv6u
David Liew drdavidliew ( View Tweet)
Abst#OP0137 at #EULAR2021: ➡️TNFi use for at least 1 year decreased radiographic sacroiliitis progression in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC) . ➡️This effect becomes evident 2-4 years after tx. @RheumNow https://t.co/GNnYqYmxhl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
SPACING trial: possible to taper TNFi in AxSpA pts in LDA ⭐️Tapering of TNFi in axSpA resulted in 88% BASDAI<4 compared to 91.5% in unchanged group ⭐️adalimumab spaced out to q35 days Abs#OP0138 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

×